SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty ph...
Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.
Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.
Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisiniclineSEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjami
Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. Click for this ACHV stock update.
SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 283,000 share
This is the newest page. Registered accounts read further back.